

ENG

Instructions for Use:
HUMAN RESISTIN ELISA

Catalogue number:
RD191016100

European Union:



Rest of the world:

For research use only.

 **BioVendor**
R&D[®]



BioVendor – Laboratorní medicína a.s.

Karásek 1767/1, 621 00 Brno, Czech Republic

+420 549 124 185

info@biovendor.com

sales@biovendor.com

www.biovendor.com

1. INTENDED USE	3
2. STORAGE, EXPIRATION	3
3. INTRODUCTION	4
4. TEST PRINCIPLE	5
5. PRECAUTIONS	5
6. TECHNICAL HINTS	5
7. REAGENT SUPPLIED	6
8. MATERIAL REQUIRED BUT NOT SUPPLIED	6
9. PREPARATION OF REAGENTS	7
10. PREPARATION OF SAMPLES	9
11. ASSAY PROCEDURE	10
12. CALCULATIONS	12
13. PERFORMANCE CHARACTERISTICS	13
14. DEFINITION OF THE STANDARD	17
15. PRELIMINARY POPULATION DATA	17
16. METHOD COMPARISON	18
17. TROUBLESHOOTING AND FAQs	19
18. REFERENCES	20
19. ADDITIONAL INFORMATION	22
20. EXPLANATION OF SYMBOLS	22
21. ASSAY PROCEDURE - SUMMARY	23

HISTORY OF CHANGES

Previous version	Current version
ENG.007.A	ENG.008.A
History of changes added.	
A symbol indicating the manufacturer added.	
Chapter 19. "Additional information" added.	

1. INTENDED USE

The RD191016100 Human Resistin ELISA is a sandwich enzyme immunoassay for the quantitative measurement of human resistin.

Features

- **European Union: for in vitro diagnostic use**
- **Rest of the world: for research use only!**
- The total assay time is less than 4 hours
- The kit measures total resistin in serum and plasma (EDTA, citrate, heparin)
- Assay format is 96 wells
- Quality Controls are human serum based
- Standard is recombinant protein based
- Components of the kit are provided ready to use, concentrated or lyophilized

2. STORAGE, EXPIRATION

Store the complete kit at 2–8°C. Under these conditions, the kit is stable until the expiration date (see label on the box).

For stability of opened reagents see Chapter 9.

3. INTRODUCTION

Resistin, a product of the RSTN gene, is a peptide hormone belonging to the class of cysteine-rich secreted proteins which is termed the RELM family and is also described as ADSF (Adipose Tissue-Specific Secretory Factor) or FIZZ3 (Found in Inflammatory Zone). Human resistin contains 108 amino acids as a prepeptide, and its hydrophobic signal peptide is cleaved before its secretion. Resistin circulates in human blood as a dimeric protein consisting of two 92 amino acid polypeptides, which are disulfide-linked via Cys26.

Much of the early investigations about the resistin molecule are based on the mouse model. Resistin, produced and secreted primarily by adipocytes in mice, acts on skeletal muscle myocytes, hepatocytes and adipocytes themselves so that it reduces their sensitivity to insulin. Stepan et al. have suggested that resistin suppresses the ability of insulin to stimulate glucose uptake. Other studies have shown that mouse resistin increases during the differentiation of adipocytes, but it also seems to inhibit adipogenesis.

Compared to the mouse model, human adipogenic differentiation is likely to be associated with a down regulation of resistin gene expression. On the other hand, resistin was found to be expressed at high levels in human monocytes, macrophages and bone marrow.

Recent investigations have shown that human resistin is correlated with metabolic syndrome and obesity-related disorders. Malo et al. have reported that resistin levels are positively associated with waist circumference, tumor necrosis factor- α , and insulin resistance assessed by the homeostasis model, and inversely correlated with total cholesterol, HDL cholesterol, and LDL cholesterol. Moreover, Sadhasiv et al. found a positive correlation of SAT (subcutaneous adipose tissue) resistin mRNA expression with serum resistin, BMI and insulin resistance (HOMA index).

Based on the above reports human resistin might be an important marker that acts as the link between obesity and insulin resistance. Resistin can play a role also in inflammation processes and in atherosclerosis.

Clinical use and areas of investigation:

Energy metabolism and body weight regulation

Metabolic syndrome

Inflammation

Atherosclerosis

4. TEST PRINCIPLE

In the BioVendor Human Resistin ELISA, standards, quality controls and samples are incubated in microplate wells pre-coated with polyclonal anti-human resistin antibody. After 60 minutes incubation and washing, biotin labelled second polyclonal anti-human resistin antibody is added and incubated with captured resistin for 60 minutes. After another washing, streptavidin-HRP conjugate is added. After 60 minutes incubation and the last washing step, the remaining conjugate is allowed to react with the substrate solution (TMB). The reaction is stopped by addition of acidic solution and absorbance of the resulting yellow product is measured. The absorbance is proportional to the concentration of resistin. A standard curve is constructed by plotting absorbance values against concentrations of standards, and concentrations of unknown samples are determined using this standard curve.

5. PRECAUTIONS

- **For professional use only**
- Wear gloves and laboratory coats when handling immunodiagnostic materials
- Do not drink, eat or smoke in the areas where immunodiagnostic materials are being handled
- This kit contains components of human origin. These materials were found non-reactive for HBsAg, HCV antibody and for HIV 1/2 antigen and antibody. However, these materials should be handled as potentially infectious, as no test can guarantee the complete absence of infectious agents
- This kit contains components of animal origin. These materials should be handled as potentially infectious
- Avoid contact with the acidic Stop Solution and Substrate Solution, which contains hydrogen peroxide and tetramethylbenzidine (TMB). Wear gloves and eye and clothing protection when handling these reagents. Stop and/or Substrate Solutions may cause skin/eyes irritation. In case of contact with the Stop Solution and the Substrate Solution wash skin/eyes thoroughly with water and seek medical attention, when necessary
- The materials must not be pipetted by mouth

6. TECHNICAL HINTS

- Reagents with different lot numbers should not be mixed
- Use thoroughly clean glassware
- Use deionized (distilled) water, stored in clean containers
- Avoid any contamination among samples and reagents. For this purpose, disposable tips should be used for each sample and reagent
- Substrate Solution should remain colourless until added to the plate. Keep Substrate Solution protected from light
- Stop Solution should remain colourless until added to the plate. The colour developed in the wells will turn from blue to yellow immediately after the addition of the Stop Solution. Wells that are green in colour indicate that the Stop Solution has not mixed thoroughly with the Substrate Solution
- Dispose of consumable materials and unused contents in accordance with applicable national regulatory requirements

7. REAGENT SUPPLIED

Kit Components	State	Quantity
Antibody Coated Microtiter Strips	ready to use	96 wells
Biotin Labelled Antibody	ready to use	13 ml
Streptavidin-HRP Conjugate	ready to use	13 ml
Master Standard	lyophilized	1 vial
Quality Control HIGH	lyophilized	1 vial
Quality Control LOW	lyophilized	1 vial
Dilution Buffer	ready to use	20 ml
Wash Solution Conc. (10x)	concentrated	100 ml
Substrate Solution	ready to use	13 ml
Stop Solution	ready to use	13 ml

8. MATERIAL REQUIRED BUT NOT SUPPLIED

- Deionized (distilled) water
- Test tubes for diluting samples
- Glassware (graduated cylinder and bottle) for Wash Solution (Dilution Buffer)
- Precision pipettes to deliver 10–1000 μl with disposable tips
- Multichannel pipette to deliver 100 μl with disposable tips
- Absorbent material (e.g. paper towels) for blotting the microtiter plate after washing
- Vortex mixer
- Orbital microplate shaker capable of approximately 300 rpm
- Microplate washer (optional). [Manual washing is possible but not preferable.]
- Microplate reader with 450 ± 10 nm filter, preferably with reference wavelength 630 nm (alternatively another one from the interval 550–650 nm)
- Software package facilitating data generation and analysis (optional)

9. PREPARATION OF REAGENTS

All reagents need to be brought to room temperature prior to use.
Always prepare only the appropriate quantity of reagents for your test.
Do not use components after the expiration date marked on their label.

Assay reagents supplied ready to use:

Antibody Coated Microtiter Strips

Stability and storage:

Return the unused strips to the provided aluminium zip-sealed bag with desiccant and seal carefully. Remaining Microtiter Strips are stable 3 months stored at 2–8°C and protected from the moisture.

Biotin Labelled Antibody

Streptavidin-HRP Conjugate

Dilution Buffer

Substrate Solution

Stop Solution

Stability and storage:

Opened reagents are stable 3 months when stored at 2–8°C.

Assay reagents supplied concentrated or lyophilized:

Human Resistin Master Standard

Refer to the Certificate of Analysis for current volume of Dilution Buffer needed for reconstitution of standard!!!

Reconstitute the lyophilized Master Standard with Dilution Buffer just prior to the assay. Let it dissolve at least 15 minutes with occasional gentle shaking (not to foam). The resulting concentration of the resistin in the stock solution is **50 ng/ml**.

Prepare set of standards using Dilution Buffer as follows:

Volume of Standard	Dilution Buffer	Concentration
Stock	-	50 ng/ml
500 µl of stock	750 µl	20 ng/ml
500 µl of 20 ng/ml	500 µl	10 ng/ml
500 µl of 10 ng/ml	500 µl	5 ng/ml
500 µl of 5 ng/ml	750 µl	2 ng/ml
500 µl of 2 ng/ml	500 µl	1 ng/ml

Dilute each concentration of standard 3x with Dilution Buffer prior to the assay, e.g. 50 µl of standard + 100 µl of Dilution Buffer for singlets, or preferably 100 µl of standard + 200 µl of Dilution Buffer for duplicates. Mix well (not to foam).

Stability and storage:

Set of standards (50–1 ng/ml) should be aliquoted and frozen at -20°C for 3 months. Avoid repeated freeze/thaw cycles.

Do not store the diluted Standard solutions.

Quality Controls HIGH, LOW

Refer to the Certificate of Analysis for current Quality Control concentration!!!

Reconstitute each Quality Control (HIGH and LOW) with 350 µl Dilution Buffer just prior to the assay. Let it dissolve at least 30 minutes with occasional gentle shaking (not to foam).

Dilute Quality Controls prior to the assay 3x with Dilution Buffer, e.g. 50 µl of Quality Control + 100 µl of Dilution Buffer for singlets, or preferably 100 µl of Quality Control + 200 µl of Dilution Buffer for duplicates.

Stability and storage:

The reconstituted Quality Controls must be used immediately or aliquoted and frozen at -20°C for 3 month. Avoid repeated freeze/thaw cycles.

Do not store the diluted Quality Controls.

Note:

Concentration of analyte in Quality Controls need not be anyhow associated with normal and/or pathological concentrations in serum or another body fluid. Quality Controls serve just for control that the kit works in accordance with IFU and CoA and that ELISA test was carried out properly.

Wash Solution Conc. (10x)

Dilute Wash Solution Concentrate (10x) ten-fold in distilled water to prepare a 1x working solution. Example: 100 ml of Wash Solution Concentrate (10x) + 900 ml of distilled water for use of all 96-wells.

Stability and storage:

The diluted Wash Solution is stable 1 month when stored at 2–8°C. Opened Wash Solution Concentrate (10x) is stable 3 months when stored at 2–8°C.

10. PREPARATION OF SAMPLES

The kit measures human resistin (homodimeric) in serum and plasma (EDTA, citrate, heparin).

Samples should be assayed immediately after collection or should be stored at -20°C. Mix thoroughly thawed samples just prior to the assay and avoid repeated freeze/thaw cycles, which may cause erroneous results. Avoid using hemolyzed or lipemic samples.

Dilute samples 3x with Dilution Buffer just prior to the assay, e.g. 50 µl of sample + 100 µl of Dilution Buffer for singlets, or preferably 100 µl of sample + 200 µl of Dilution Buffer for duplicates. **Mix well** (not to foam). Vortex is recommended.

Stability and storage:

Samples should be stored at -20°C, or preferably at -70°C for long-term storage.

Do not store the diluted samples.

See Chapter 13 for stability of serum and plasma samples when stored at 2–8°C, effect of freezing/thawing and effect of sample matrix (serum/plasma) on the concentration of human resistin.

Note: It is recommended to use a precision pipette and a careful technique to perform the dilution in order to get precise results.

Ask for information at info@biovendor.com if assaying tissue culture supernatants or synovial fluid.

11. ASSAY PROCEDURE

1. Pipet **100 µl** of diluted Standards, Quality Controls, Dilution Buffer (= Blank) and samples, preferably in duplicates, into the appropriate wells. See *Figure 1* for example of work sheet.
2. Incubate the plate at room temperature (ca. 25°C) for **1 hour**, shaking at ca. 300 rpm on an orbital microplate shaker.
3. Wash the wells 3-times with Wash Solution (0.35 ml per well). After final wash, invert and tap the plate strongly against paper towel.
4. Add **100 µl** of Biotin Labelled Antibody solution into each well.
5. Incubate the plate at room temperature (ca. 25°C) for **1 hour**, shaking at ca. 300 rpm on an orbital microplate shaker.
6. Wash the wells 3-times with Wash Solution (0.35 ml per well). After final wash, invert and tap the plate strongly against paper towel.
7. Add **100 µl** of Streptavidin-HRP Conjugate into each well.
8. Incubate the plate at room temperature (ca. 25°C) for **1 hour**, shaking at ca. 300 rpm on an orbital microplate shaker.
9. Wash the wells 3-times with Wash Solution (0.35 ml per well). After final wash, invert and tap the plate strongly against paper towel.
10. Add **100 µl** of Substrate Solution into each well. Avoid exposing the microtiter plate to direct sunlight. Covering the plate with e.g. aluminium foil is recommended.
11. Incubate the plate for **10 minutes** at room temperature. The incubation time may be extended [up to 20 minutes] if the reaction temperature is below than 20°C. Do not shake the plate during the incubation.
12. Stop the colour development by adding **100 µl** of Stop Solution.
13. Determine the absorbance of each well using a microplate reader set to 450 nm, preferably with the reference wavelength set to 630 nm (acceptable range: 550–650 nm). Subtract readings at 630 nm (550–650 nm) from the readings at 450 nm. **The absorbance should be read within 5 minutes following step 12.**

Note 1: If some samples and standard/s have absorbances above the upper limit of your microplate reader, perform a second reading at 405 nm. A new standard curve, constructed using the values measured at 405 nm, is used to determine resistin concentration of off-scale standards and samples. The readings at 405 nm should not replace the readings for samples that were “in range” at 450 nm.

Note 2: Manual washing: Aspirate wells and pipet 0.35 ml Wash Solution into each well. Aspirate wells and repeat twice. After final wash, invert and tap the plate strongly against paper towel. Make certain that Wash Solution has been removed entirely.

	strip 1+2	strip 3+4	strip 5+6	strip 7+8	strip 9+10	strip 11+12
A	Standard 50	QC LOW	Sample 8	Sample 16	Sample 24	Sample 32
B	Standard 20	Sample 1	Sample 9	Sample 17	Sample 25	Sample 33
C	Standard 10	Sample 2	Sample 10	Sample 18	Sample 26	Sample 34
D	Standard 5	Sample 3	Sample 11	Sample 19	Sample 27	Sample 35
E	Standard 2	Sample 4	Sample 12	Sample 20	Sample 28	Sample 36
F	Standard 1	Sample 5	Sample 13	Sample 21	Sample 29	Sample 37
G	Blank	Sample 6	Sample 14	Sample 22	Sample 30	Sample 38
H	QC HIGH	Sample 7	Sample 15	Sample 23	Sample 31	Sample 39

Figure 1: Example of a work sheet.

12. CALCULATIONS

Most microplate readers perform automatic calculations of analyte concentration. The standard curve is constructed by plotting the mean absorbance (Y) of Standards against the known concentration (X) of Standards in logarithmic scale, using the four-parameter algorithm. Results are reported as concentration of resistin ng/ml in samples.

Alternatively, the logit log function can be used to linearize the standard curve, i.e. logit of the mean absorbance (Y) is plotted against log of the known concentration (X) of Standards.

Samples, Quality Controls and Standards are all diluted 3x prior to analysis, so there is no need to take this dilution factor into account.




Figure 2: Typical Standard Curve for Human Resistin ELISA.

13. PERFORMANCE CHARACTERISTICS

Typical analytical data of BioVendor Human Resistin ELISA are presented in this chapter.

Sensitivity

Limit of Detection (LOD) (defined as concentration of analyte giving absorbance higher than mean absorbance of blank* plus three standard deviations of the absorbance of blank: $A_{blank} + 3 \times SD_{blank}$) is calculated from the real human resistin values in wells and is 0.012 ng/ml. *Dilution Buffer is pipetted into blank wells.

Limit of assay

Results exceeding resistin level of 50 ng/ml should be repeated with more diluted samples. Dilution factor needs to be taken into consideration in calculating the resistin concentration.

Specificity

The antibodies used in this ELISA are specific for human resistin with no detectable crossreactivities to human leptin, leptin receptor, RELM-beta, A-FABP and E-FABP at 100 ng/ml and adiponectin at 10 µg/ml.

Determination of resistin does not interfere with hemoglobin (1.0 mg/ml), bilirubin (170 µmol/l) and triglycerides (5.0 mmol/l).

Sera of several mammalian species were measured in the assay. See results below. For details please contact us at info@biovendor.com.

Mammalian serum sample	Observed crossreactivity
Bovine	no
Cat	no
Dog	no
Goat	no
Hamster	no
Horse	yes
Monkey	yes
Mouse	yes
Pig	yes
Rabbit	no
Rat	no
Sheep	no

Precision

Intra-assay (Within-Run) (n=8)

Sample	Mean (ng/ml)	SD (ng/ml)	CV (%)
1	6.34	0.33	5.2
2	17.53	1.16	6.6

Inter-assay (Run-to-Run) (n=5)

Sample	Mean (ng/ml)	SD (ng/ml)	CV (%)
1	6.66	0.47	7.0
2	23.52	1.90	8.1

Spiking Recovery

Serum samples were spiked with different amounts of human resistin and assayed.

Sample	Observed (ng/ml)	Expected (ng/ml)	Recovery O/E (%)
1	4.04	-	-
	8.61	9.04	95.3
	12.27	14.04	87.4
	21.99	24.04	91.5
2	4.85	-	-
	9.44	9.85	95.8
	12.98	14.85	87.4
	22.06	24.85	88.8

Linearity

Serum samples were serially diluted with Dilution Buffer and assayed.

Sample	Dilution	Observed (ng/ml)	Expected (ng/ml)	Recovery O/E (%)
1	-	15.05	-	-
	2x	8.53	7.53	113.4
	4x	3.62	3.76	96.1
	8x	1.83	1.88	97.1
2	-	26.44	-	-
	2x	11.26	13.22	85.2
	4x	6.09	6.61	92.1
	8x	3.06	3.30	92.7

Effect of sample matrix

Heparin, citrate and EDTA plasmas were compared to respective serum samples from the same 10 individuals. Results are shown below:

Volunteer No.	Serum (ng/ml)	Plasma (ng/ml)		
		EDTA	Citrate	Heparin
1	5.13	5.66	4.54	6.60
2	9.99	10.07	8.97	11.69
3	7.22	7.20	6.31	9.53
4	3.89	4.39	3.43	3.96
5	2.31	2.95	2.25	2.78
6	7.02	7.86	8.12	12.29
7	10.47	11.47	9.48	14.62
8	4.85	4.74	4.14	7.09
9	5.22	5.11	4.40	6.41
10	4.82	5.68	4.85	5.80
Mean (ng/ml)	6.09	6.51	5.65	8.08
Mean Plasma/Serum (%)		106.9 %	92.7 %	132.6 %
Coefficient of determination R²		0.97	0.94	0.89




Figure 3: Resistin levels measured using Human Resistin ELISA from 10 individuals using serum, EDTA, citrate and heparin plasma, respectively.

Stability of samples stored at 2–8°C

Samples should be stored at -80°C. However, no decline in concentration of resistin was observed in serum and plasma samples after 7 days when stored at 2–8°C. To avoid microbial contamination, samples were treated with ϵ -aminocaproic acid and sodium azide, resulting in the final concentration of 0.03% and 0.1 %, respectively.

Sample	Incubation Temp, Period	Serum (ng/ml)	Plasma (ng/ml)		
			EDTA	Citrate	Heparin
1	-80°C	4.11	4.60	4.31	5.04
	2–8°C, 1 day	4.23	4.76	3.77	4.59
	2–8°C, 7 days	4.27	4.84	3.69	4.95
2	-80°C	6.21	6.63	5.18	7.95
	2–8°C, 1 day	6.46	6.79	5.17	8.91
	2–8°C, 7 days	7.12	6.24	5.06	8.47
3	-80°C	9.62	9.85	9.72	12.94
	2–8°C, 1 day	9.17	9.74	8.33	12.23
	2–8°C, 7 days	8.71	9.85	8.91	12.18

Effect of Freezing/Thawing

No decline was observed in concentration of human resistin in serum and plasma samples after repeated (3x) freeze/thaw cycles. However it is recommended to avoid unnecessary repeated freezing/thawing of the samples.

Sample	Number of f/t cycles	Serum (ng/ml)	Plasma (ng/ml)		
			EDTA	Citrate	Heparin
1	1x	2.31	2.38	2.29	2.63
	3x	2.13	2.24	2.35	2.47
	5x	1.94	2.15	2.38	2.36
2	1x	3.58	4.38	3.35	3.65
	3x	3.65	5.04	3.23	3.74
	5x	3.64	4.57	3.26	4.32
3	1x	4.34	4.73	3.92	5.58
	3x	4.53	5.14	4.11	5.49
	5x	3.97	4.64	3.42	4.96

14. DEFINITION OF THE STANDARD

A recombinant protein is used as the standard. The recombinant resistin is a 19.5 kDa dimeric protein consisting of two 92 amino acid polypeptide chains which are disulfide-linked.

15. PRELIMINARY POPULATION DATA

The following results were obtained when serum samples from 155 unselected donors (89 men + 66 women) 20–65 years old were assayed with the BioVendor Human Resistin ELISA in our laboratory.

Sex	Age (years)	n	Resistin (ng/ml)				
			Mean	Median	SD	Min	Max
Men	20-29	17	4.28	4.01	1.19	2.73	7.21
	30-39	25	4.83	4.80	1.20	2.12	6.92
	40-49	31	3.96	3.99	0.83	2.59	6.51
	50-65	16	4.34	3.86	1.37	2.12	6.84
Women	20-29	12	4.63	4.47	0.85	3.63	6.96
	30-39	26	5.11	4.49	1.40	3.20	8.85
	40-49	20	4.67	4.39	1.14	2.55	6.71
	50-61	8	3.56	2.91	1.10	2.42	5.67




Figure 4: Human resistin concentration plotted against donor age and sex.

Reference range

The data quoted in these instructions should be used for guidance only. It is recommended that each laboratory include its own panel of control samples in the assay. Each laboratory should establish its own normal and pathological reference ranges for human resistin protein levels with the assay.

16. METHOD COMPARISON

The BioVendor Resistin ELISA was compared to the other commercial ELISA assay, by measuring 78 serum samples. The following correlation graph was obtained.




Figure 5: Method comparison.

17. TROUBLESHOOTING AND FAQs

Weak signal in all wells

Possible explanations:

- Omission of a reagent or a step
- Improper preparation or storage of a reagent
- Assay performed before reagents were allowed to come to room temperature
- Improper wavelength when reading absorbance

High signal and background in all wells

Possible explanations:

- Improper or inadequate washing
- Overdeveloping; incubation time with Substrate Solution should be decreased before addition of Stop Solution
- Incubation temperature over 30°C

High coefficient of variation (CV)

Possible explanation:

- Improper or inadequate washing
- Improper mixing Standards, Quality Controls or samples

Example Version

18. REFERENCES

References to human resistin:

- Sadashiv, Tiwari S, Paul BN, Kumar S, Chandra A, Dhananjai S, Negi MP. Over expression of resistin in adipose tissue of the obese induces insulin resistance. *World J Diabetes*; 3(7):135-141 (2012)
- Malo E, Ukkola O, Jokela M, Moilanen L, Kähönen M, Nieminen MS, Salomaa V, Jula A, Kesäniemi YA. Resistin is an indicator of the metabolic syndrome according to five different definitions in the Finnish Health 2000 survey. *Metab Syndr Relat Disord*; 9(3):203-210 (2011)
- Lazar MA. Resistin- and Obesity-associated metabolic diseases. *Horm Metab Res*; 39(10):710-716 (2007)
- Meier U, Gressner AM. Endocrine regulation of energy metabolism: review of pathobiochemical and clinical chemical aspects of leptin, ghrelin, adiponectin, and resistin. *Clin Chem*; 50(9):1511-1525 (2004)
- Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. *J Clin Endocrinol Metab*; 89(6):2548-2556 (2004)
- Hartman HB, Hu X, Tyler KX, Dalal CK, Lazar MA. Mechanisms Regulating Adipocyte Expression of Resistin. *J Biol Chem*; 277(22):19754-19761 (2002)
- Stepan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM, Patel HR, Ahima RS, Lazar MA. The Hormone Links Obesity to Diabetes. *Nature*; 409 (6818):307-312 (2001)

References to this product:

- Aknc A, Karakurt C, Gurbuz S, Elkran O, Nalbantoglu O, Kocak G, Guldur T, Yologlu S. Association of cardiac changes with serum adiponectin and resistin levels in obese and overweight children. *J Cardiovasc Med (Hagerstown)*; [Epub ahead of print] (2012)
- Menzaghi C, Salvemini L, Fini G, Thompson R, Mangiacotti D, Di Paola R, Morini E, Giorelli M, De Bonis C, De Cosmo S, Doria A, Trischitta V. Serum resistin and kidney function: a family-based study in non-diabetic, untreated individuals. *PLoS One*; 7(6):e38414 (2012)
- Sadashiv, Tiwari S, Paul BN, Kumar S, Chandra A, Dhananjai S, Negi MP. Over expression of resistin in adipose tissue of the obese induces insulin resistance. *World J Diabetes*; 3(7):135-141 (2012)
- Gupta V, Singh AK, Gupta V, Kumar S, Srivastava N, Jafar T, Pant AB. Association of circulating resistin with metabolic risk factors in Indian females having metabolic syndrome. *Toxicol Int*; 18(2):168-172 (2011)
- De Luis DA, Gonzalez Sagrado M, Conde R, Aller R, Izaola O, Primo D. Lack of association of serum resistin levels with metabolic syndrome criteria in obese female patients. *Clin Biochem*; 44(16):1280-1283 (2011)
- De Luis DA, Terroba MC, Cuellar L, Conde R, Primo D, Aller R, Sagrado MG, Izaola O. Resistin Levels in Morbid Obese Patients Following the Biliopancreatic Diversion Surgery. *Horm Metab Res*; 43(3):205-208 (2011)
- Thomopoulos C, Daskalaki M, Papazachou O, Rodolakis N, Bratsas A, Papadopoulos DP, Papavasileiou MV, Perrea D, Makris T. Association of resistin and adiponectin with different clinical blood pressure phenotypes. *J Hum Hypertens*; 25(1):38-46 (2011)
- De Luis DA, González Sagrado M, Conde R, Aller R, Izaola O. Resistin levels and inflammatory markers in patients with morbid obesity. *Nutr Hosp*; 25(4):630-4 (2010)
- Gupta A, Gupta V, Singh AK, Tiwari S, Agrawal S, Natu SM, Agrawal CG, Negi MP, Pant AB. Interleukin-6 G-174C gene polymorphism and serum resistin levels in North Indian women: potential risk of metabolic syndrome. *Hum Exp Toxicol*; [Epub ahead of print] (2010)
- Koch A, Gressner OA, Sanson E, Tacke F, Trautwein C. Serum resistin levels in critically ill patients are associated with inflammation, organ dysfunction and metabolism and may predict survival of non-septic patients. *Crit Care*; 13(3):R95 (2009)












- Papadopoulos DP, Perrea D, Thomopoulos C, Sanidas E, Daskalaki M, Papazachou U, Votteas V, Makris T. Masked hypertension and atherogenesis: the impact on adiponectin and resistin plasma levels. *J Clin Hypertens (Greenwich)*; 11(2):61-5 (2009)
- Elloumi M, Ben Ounis O, Makni E, Van Praagh E, Tabka Z, Lac G. Effect of individualized weight-loss programmes on adiponectin, leptin and resistin levels in obese adolescent boys. *Acta Paediatr*; 98(9):1487-93 (2009)
- Sheng CH, Di J, Jin Y, Zhang YC, Wu M, Sun Y, Zhang GZ. Resistin is expressed in human hepatocytes and induces insulin resistance. *Endocrine*; 33(2):135-43 (2008)
- Busetto L, Bassetto F, Zocchi M, Zuliani F, Nolli ML, Pigozzo S, Coin A, Mazza M, Sergi G, Mazzoleni F, Enzi G. The effects of the surgical removal of subcutaneous adipose tissue on energy expenditure and adipocytokine concentrations in obese women. *Nutr Metab Cardiovasc Dis*; 18(2):112-120 (2008)
- Cortelazzi D, Corbetta S, Ronzoni S, Pelle F, Marconi A, Cozzi V, Cetin I, Cortelazzi R, Beck-Peccoz P, Spada A. Maternal and foetal resistin and adiponectin concentrations in normal and complicated pregnancies. *Clin Endocrinol*; 66(3):447-53 (2007)
- Hoefle G, Saely CH, Risch L, Koch L, Schmid F, Rein P, Aczél S, Berchtold S, Drexel H. Relationship between the adipose-tissue hormone resistin and coronary artery disease. *Clin Chim Acta*; 386(1-2):1-6 (2007)
- Lubos E, Messow CM, Schnabel R, Rupprecht HJ, Espinola-Klein C, Bickel C, Peetz D, Post F, Lackner KJ, Tiret L, Munzel T, Blankenberg S. Resistin, acute coronary syndrome and prognosis results from the AtheroGene study. *Atherosclerosis*; 193(1):121-128 (2007)
- Hui-Bing H, Migita K, Miyashita T, Maeda Y, Nakamura M, Yatsushashi H, Ishibashi H, Eguchi K, Kimura. Relationship between serum resistin concentrations and inflammatory markers in patients with type 2 diabetes mellitus. *Metabolism*; 55(12):1670-3 (2006)
- Burnett MS, Devaney JM, Adenika RJ, Lindsay R, Howard BV. Cross-sectional associations of resistin, coronary heart disease, and insulin resistance. *J Clin Endocrinol Metab*; 91(1):64-8 (2006)
- Taniguchi H, Ogura M, Ayaori M, Nakamura H, Ohsuzu F: Associations between serum resistin levels and insulin resistance, inflammation, and coronary artery disease. *J Am Coll Cardiol*; 46(2):379-80 (2005)
- Reilly MP, Lehrke M, Wolfe ML, Rohatgi A, Lazar MA, Rader DJ: Resistin is an inflammatory marker of atherosclerosis in humans. *Circulation*; 111(7):932-9 (2005)
- Schaffler A, Buchler C, Muller-Ladner U, Herfarth H, Ehling A, Paul G, Scholmerich J, Zietz B: Identification of variables influencing resistin serum levels in patients with type 1 and type 2 diabetes mellitus. *Horm Metab Res*; 36(10):702-7 (2004)
- Heilbronn LK, Rood J, Janderova L, Albu JB, Kelley DE, Ravussin E, Smith SR: Relationship between serum resistin concentrations and insulin resistance in nonobese, obese, and obese diabetic subjects. *J Clin Endocrinol Metab*; 89(4):1844-8 (2004)
- Stejskal D, Adamovska S, Bartek J, Jurakova R, Proskova J: Resistin - concentrations in persons with type 2 diabetes mellitus and in individuals with acute inflammatory disease. *Biomed Papers*; 147(1):63-9 (2003)

For more references on this product see our web pages at www.biovendor.com.


19. ADDITIONAL INFORMATION

Any serious incident occurring in connection with the device must be reported to the manufacturer and to the competent authority of the Member State in which the user or patient is located.

20. EXPLANATION OF SYMBOLS

	Catalogue number
	Batch code
	Caution
	Use by date
	Temperature limit
	Manufacturer
 www.biovendor.com	Read electronic instructions for use - eIFU
	The content is sufficient for 96 tests
	Biological risks
	In vitro diagnostic medical device
	CE marking of conformity

21. ASSAY PROCEDURE - SUMMARY





BioVendor – Laboratorní medicína a.s.

Karásek 1767/1, 621 00 Brno, Czech Republic

+420 549 124 185

info@biovendor.com

sales@biovendor.com

www.biovendor.com

Date of last revision: 18.07.2024

